Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia

References

• Hammond SP, Marty FM, Bryar JM, et al. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol. 2010;85(9):695–699.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Lu K, Hatfield-Seung A, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis. 2013;75(2):144–149.
   PubMed Web of Science ®Google Scholar
• Gerber B, Koppel J, Paul M, et al. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study. Swiss Med Wkly. 2014;144:w13985.
   PubMed Web of Science ®Google Scholar
• Tang JL, Kung HC, Lei WC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS One. 2015;10(6):e0128410.
   PubMed Web of Science ®Google Scholar
• Xu XH, Zhang L, Cao XX, et al. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. J Infect Chemother. 2017;23(6):360–367.
   PubMed Web of Science ®Google Scholar
• Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: analysis of the acute leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma. 2012;53(6):1068–1076.
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19(8):745–751.
   PubMed Web of Science ®Google Scholar
• van de Peppel RJ, Dekkers OM, von Dem Borne PA, et al. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. Med Mycol. 2014;52(7):699–705.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55(5):445–449.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466–1471.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043–3054.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections versions 2.2020. National Comprehensive Cancer Network; 2020; [cited 2020 Mar 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
   Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373–379.
   PubMed Web of Science ®Google Scholar
• Brook O, Guralnik L, Hardak E, et al. Radiological findings of early invasive pulmonary aspergillosis in immune-compromised patients. Hematol Oncol. 2009;27(2):102–106.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. Wayne, Pennsylvania, United States: Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55(10):1352–1361.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40(4):1298–1302.
   PubMed Web of Science ®Google Scholar
• Lien MY, Chou CH, Lin CC, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study. PLOS One. 2018;13(6):e0197851.
   PubMed Web of Science ®Google Scholar